Table 2.
HRs for Disease-Free and Overall Survival by CRP and SAA Tertiles
| Tertile | No. of Events | No. of Participants | Model 1* |
Model 2† |
Model 3‡ |
Model 4§ |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P (trend) | HR | 95% CI | P (trend) | HR | 95% CI | P (trend) | HR | 95% CI | P (trend) | |||
| Overall survival‖ | 88 | 734 | ||||||||||||
| CRP, mg/L | ||||||||||||||
| ≤ 1.2 | 24 | 260 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | ||||
| 1.3-3.8 | 22 | 237 | 0.81 | 0.44 to 1.48 | 0.92 | 0.50 to 1.73 | 0.91 | 0.48 to 1.69 | 0.94 | 0.50 to 1.76 | ||||
| ≥ 3.9 | 42 | 237 | 1.90 | 1.11 to 3.23 | .01 | 2.31 | 1.30 to 4.12 | .002 | 2.27 | 1.27 to 4.08 | .002 | 2.05 | 1.14 to 3.69 | .01 |
| SAA, mg/L | ||||||||||||||
| ≤ 4.2 | 18 | 252 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | ||||
| 4.3-8.0 | 20 | 238 | 0.89 | 0.46 to 1.73 | 0.98 | 0.50 to 1.90 | 0.99 | 0.51 to 1.93 | 0.97 | 0.49 to 1.89 | ||||
| ≥ 8.1 | 50 | 244 | 2.67 | 1.53 to 4.63 | .0001 | 3.08 | 1.73 to 5.47 | .0001 | 3.15 | 1.76 to 5.65 | .0001 | 2.91 | 1.61 to 5.26 | .0001 |
| lnCRP | 88 | 734 | 1.28 | 1.06 to 1.53 | 1.39 | 1.14 to 1.70 | 1.39 | 1.14 to 1.69 | 1.25 | 1.02 to 1.54 | ||||
| lnSAA | 88 | 734 | 1.42 | 1.24 to 1.88 | 1.55 | 1.29 to 1.99 | 1.61 | 1.30 to 2.01 | 1.42 | 1.10 to 1.82 | ||||
| Disease-free survival¶ | 91 | 728 | ||||||||||||
| CRP, mg/L | ||||||||||||||
| ≤ 1.2 | 23 | 260 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | ||||
| 1.3-3.8 | 31 | 236 | 1.40 | 0.80 to 2.44 | 1.59 | 0.89 to 2.84 | 1.56 | 0.87 to 2.80 | 1.58 | 0.88 to 2.83 | ||||
| ≥ 3.9 | 37 | 232 | 1.71 | 0.99 to 2.95 | .05 | 2.08 | 1.14 to 3.77 | .02 | 1.99 | 1.09 to 3.65 | .03 | 1.91 | 1.04 to 3.51 | .04 |
| SAA, mg/L | ||||||||||||||
| ≤ 4.2 | 26 | 251 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | ||||
| 4.3-8.0 | 24 | 237 | 0.93 | 0.52 to 1.65 | 0.97 | 0.55 to 1.72 | 1.02 | 0.57 to 1.81 | 1.00 | 0.56 to 1.79 | ||||
| ≥ 8.1 | 41 | 240 | 1.54 | 0.92 to 2.57 | .08 | 1.65 | 0.97 to 2.81 | .05 | 1.67 | 0.97 to 2.86 | .05 | 1.62 | 0.94 to 2.80 | .07 |
| lnCRP | 91 | 728 | 1.15 | 0.97 to 1.37 | 1.23 | 1.01 to 1.49 | 1.21 | 1.00 to 1.48 | 1.17 | 0.97 to 1.44 | ||||
| lnSAA | 91 | 728 | 1.29 | 1.02 to 1.63 | 1.34 | 1.05 to 1.71 | 1.35 | 1.06 to 1.73 | 1.29 | 0.99 to 1.68 | ||||
Abbreviations: HR, hazard ratio; CRP, C-reactive protein; SAA, serum amyloid A; BMI, body mass index.
Adjusted for age (continuous), disease stage, and race/study site.
Adjusted for age (continuous), disease stage, race/study site, and BMI (continuous).
Adjusted for age (continuous), disease stage, race/study site, BMI (continuous), and estrogen receptor/progesterone receptor status.
Adjusted for age (continuous), disease stage, race/study site, BMI (continuous), estrogen receptor/progesterone receptor status, and cardiovascular events (histories of heart failure and myocardial infarction).
Data on overall survival collected through April 30, 2008.
Data on disease-free survival collected through September 30, 2004.